How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
Related Articles
Maplirpacept for the treatment of DLBCL: Mechanism of action and ongoing trials
Maplirpacept, a CD47-binding fusion protein, is currently being investigated in combination with other approved lymphoma therapies in early-phase trials.
Maplirpacept for the treatment of DLBCL: Mechanism of action and ongoing trials
Maplirpacept, a CD47-binding fusion protein, is currently being investigated in combination with other approved lymphoma therapies in early-phase trials.
Glenmark – Welcome to Glenmark Pharmaceuticals
Glenmark Pharma is discovering advance therapies for a new world. We are creating centers of excellence in dermatology, oncology and…
EHA 2025: Top abstracts in Lymphoma and CLL
To help navigate the exciting content being presented at the EHA Congress 2025, the Lymphoma Hub Steering Committee have provided their recommendations for the top…
European Commission approves fixed-duration acalabrutinib + venetoclax ± obinutuzumab for adult patients with previously untreated CLL
On June 6, 2025, the European Commission approved fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated…
FDA grants Breakthrough Therapy Designation to iopofosine I 131 for treatment of R/R WM
On June 4, 2025, the FDA granted Breakthrough Therapy Designation for iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia.
Brentuximab vedotin in combination with ECADD approved by the EC for patients with ND Stage IIb/III/IV Hodgkin lymphoma
On June 3, 2025, the European Commission approved brentuximab vedotin, in combination with ECADD chemotherapy, for adult patients with newly diagnosed Stage IIb with risk…
Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL | Lymphoma Hub
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL
The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for…
Newsletter | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease